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Abstract
The ovarian cancer, also known as “silent killer”, has remained the most 
lethal gynaecological malignancy. The single independent risk factor linked with 
improved survival is maximum cytoreductive effort resulting in no macroscopic 
residual disease. This could be gained through ultra-radical surgery which demands 
tackling significant tumour burden in pelvis, lower and upper abdomen which 
usually constitutes bowel resection, liver mobilisation, ancillary cholecystectomy, 
extensive peritonectomy, diaphragmatic resection, splenectomy, resection of 
enlarged pelvic, paraaortic, and rarely cardio-phrenic lymph nodes in order to 
achieve optimal debulking. The above can be achieved through a holistic approach 
to patient’s care, meticulous patient selection, and full engagement of the family. 
The decision needs to be carefully balanced after obtaining an informed consent, 
and an appreciation of the impact of such surgery on the quality of life against the 
survival benefit. This chapter will describe the complexity and surgical challenges 
in the management of advanced ovarian cancer.
Keywords: ovarian cancer, stage III and IV, cytoreductive surgery,  
ultraradical surgery, residual disease, holistic approach, quality of life
1. Introduction
The most common gynaecological cancer treated in women is uterine cancer, 
however the number of women who die from ovarian cancer is much higher [1]. 
Ovarian cancer has remained the most lethal cancer treated by gynaecological 
oncological surgeons and is often referred to as the “silent killer”.
Ovarian cancer is the 7th most common cancer, and 8th most common cause of 
death from cancer in women in the world [2]. World Ovarian Cancer Coalition 2018 
estimated that by 2035, the incidence of ovarian cancer will increase to 371, 000 per 
year. It is currently around 239, 000 cases annually [2]. The crude incidence is 23 
to 30 in 100 000 women and most women present with advanced disease and little 
prospect of cure; the five-year survival rate for all stages of ovarian cancer is just 
over 40% and has remained quite low [3].
The treatment for patients with ovarian cancer is debulking surgery and platinum-
based chemotherapy. The amount of residual disease after surgery is the most 
important prognostic factor for survival [4–11] and a recent phase III clinical trial [9] 
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Carcinoma of the Ovary
Stage I: Tumour confined to ovaries
IA. Tumour limited to 1 ovary, capsule intact, no tumour on surface, negative washings
IB. Tumour involves both ovaries otherwise like IA
IC. Tumour limited to 1 or both ovaries
IC1. Surgical spill
IC2. Capsule rupture before surgery or tumour on ovarian surface
IC3. Malignant cells in the ascites or peritoneal washings
Stage II: Tumour involves 1 or both ovaries with pelvic extension (below the pelvic brim) or primary 
peritoneal cancer
IIA. Extension and/or implant on uterus and/or fallopian tubes
IIB. Extension to other pelvic intraperitoneal tissues
Stage III: Tumour involves 1 or both ovaries, confirmed spread to extra-pelvic peritoneum and/or metastasis 
to the retroperitoneal lymph nodes
IIIA. Positive retroperitoneal lymph nodes and/or microscopic metastasis beyond the pelvis
IIIA1. Positive retroperitoneal lymph nodes only
IIIA1(i). Metastasis ≤10 mm
IIIA1(ii). Metastasis >10 mm
IIIA2. Microscopic, extra-pelvic (above the brim) peritoneal involvement ± positive retroperitoneal lymph 
nodes
IIIB. Macroscopic, extra-pelvic, peritoneal metastasis ≤2 cm ± positive retroperitoneal lymph nodes. Includes 
extension to capsule of liver/spleen.
IIIC. Macroscopic, extra-pelvic, peritoneal metastasis >2 cm ± positive retroperitoneal lymph nodes. Includes 
extension to capsule of liver/spleen.
Stage IV: Distant metastasis excluding peritoneal metastasis
IVA. Pleural effusion with positive cytology
IVB. Hepatic and/or splenic parenchymal metastasis, metastasis to extra-abdominal organs (including 
inguinal lymph nodes and lymph nodes outside of the abdominal cavity)
Table 1. 
Ovarian cancer staging (Society of Gynaecologic Oncology).
confirmed this finding. Debulking surgery is a multi-visceral operation involving the 
pelvis, lower and upper abdomen, aiming at a complete resection (CR) of all visible 
disease to a microscopic cellular level [8–11]. This is also called cytoreductive surgery.
We present the latest surgical developments in ultra-radical surgery for the 
management of advanced ovarian cancer.
2. Evolution of gynaecological oncology surgery
Gynaecological oncological surgery has a rather interesting evolution. This is 
evident in the management of uterine and vulval cancers, where there has been 
transition to less aggressive surgery. In vulval cancer the utilisation of sentinel node 
biopsy plays a major role to reduce the morbidity associated with lymphadenectomy, 
whilst the application of minimal access surgery in the management of uterine 
cancer, has ensured faster surgical recovery and significantly shortened length of 
hospital stay. In contrast, the surgical approach to ovarian cancer has gone through 
an inverse transition in the last twenty years and despite all efforts to optimise 
3
The Role of Ultra-Radical Surgery in the Management of Advanced Ovarian Cancer: State or Art
DOI: http://dx.doi.org/10.5772/intechopen.97638
medical management throughout the introduction of targeted therapies, surgery has 
remained the mainstay of treatment and has progressively more radical [12].
In ovarian cancer, a midline laparotomy is usually performed to fully access 
anatomical structures in the pelvis and intra-abdominal cavity. With a midline 
laparotomy the patient will have a longer hospital stay, as opposed to laparoscopy, 
or robotic surgery.
Minimally invasive surgery can be performed when the disease is confined to 
the primary site (stage I ovarian cancer). In widespread disease, total hysterectomy 
with bilateral salpingo-oophorectomy, infracolic omentectomy and systematic pel-
vic/para-aortic lymphadenectomy are required in order to determine the need for 
adjuvant treatment and complete full surgical staging. However, the latter does not 
regularly apply to ovarian cancer since 80% of patients with ovarian cancer present 
with advanced disease (stages III and IV) Advanced disease implies a short time for 
management and treatment; as usually the cancer has spread to the upper abdomen, 
mandating multi-visceral resection.
Before effective treatment can be offered for ovarian cancer, the disease needs 
to be correctly staged. This can be achieved by means of radiological modalities 
or exploratory laparoscopy, or a combination of both. Ovarian cancer staging is 
presented in Table 1 [13].
3. Ovarian cancer treatment
3.1 Background
Historically the treatment of ovarian cancer was primary debulking surgery 
followed by chemotherapy, whenever it was deemed to be feasible.
When to perform the debulking surgery in advanced ovarian cancer (AOC) has 
been the cause of debate and controversy for almost a decade [14]. The supporters 
of primary debulking surgery (PDS) advocate significantly better overall survival 
(OS) and progression-free survival (PFS) rates, whilst the opponents argue higher 
surgical morbidity and often fatal disease [14–17]. It is well recognised that for 
each 10% increase in maximal cytoreduction, there is an associated 5.5% increase 
in median survival [14, 18, 19]. However, in the vast majority of cases, complete 
debulking is associated with multivisceral resection which requires extensive surgi-
cal expertise, training and infrastructural support.
Neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) have 
been considered as means to reduce surgical morbidity.
In 2010, Vergote et al. conducted a phase III randomised control trial (EORTC) 
[9] where neoadjuvant chemotherapy followed by interval debulking surgery (IDS) 
was compared with upfront primary debulking surgery (PDS) followed by adjuvant 
chemotherapy. This trial demonstrated that survival in both arms was similar (29 
and 30 months, respectively), however there was less morbidity in patients who had 
chemotherapy first, mainly in those cases deemed difficult to operate [9]. The same 
findings were corroborated by the CHORUS phase III randomised controlled trial 
[20] that was used as a benchmark to justify the role of neoadjuvant chemotherapy 
in patients who were not candidates for upfront surgery. The survival remained 22 
and 24 months, respectively. There have been many debates since the publication of 
these two RCTs, with regards to survival outcome and the need for a more radical 
surgical approach, in order to achieve complete cytoreduction.
The Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (TRUST) 
will hopefully enlighten the adequate management of patients with AOC and will 
also establish predictive and prognostic biomarkers of operability and survival, 
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as well as identify valid fragility scores for vulnerable patients, with the aim of 
obtaining a more individualised surgical approach [14, 21].
Radical procedures to resect advanced ovarian cancer have been reported since 
1965 [22]. In the late 70′s the “peritoneal compartment” concept was developed, 
with the introduction of en-bloc resection of pelvic organs and the surrounding 
peritoneum [23]. The logic of en-bloc resection is based on the notion of ovar-
ian cancer as a peritoneal disease, where the peritoneum acts as a dissemination 
conduit but also limiting the spread. In fact, it is less frequent to see dissemina-
tion to the retroperitoneal organs. The en-bloc resection aims at seeking dissec-
tion planes within healthy tissue, minimising tumour manipulation and avoiding 
cutting through cancer tissue. Rapid tumour growth is usually supported by 
significant angiogenesis, primarily at the tumour periphery. As a result, there 
is a distortion of normal anatomy and findings of aberrant vascularisation. 
Therefore, a surgical technique that finds cleavage planes beyond the tumour 
growth is likely to reduce blood loss.
Visceral-Peritoneal Debulking (VPD) is offered to patients with stage III–IV 
ovarian cancer [24]. VPD applies the concept of en-bloc resection to all abdominal 
quadrants.
Maximal cytoreductive surgery aims at total macroscopic tumour clearance 
combined with platinum-based chemotherapy, these being the cornerstone of 
modern primary epithelial ovarian cancer (EOC) management [25]. Numerous 
prospective and retrospective series have demonstrated a strong positive association 
between total macroscopic tumour clearance rates and survival [25, 26]. A study 
comparing a surgical population, with a population who received chemotherapy 
alone (in 2 different cancer centres) showed that 43.8% of patients who had surgery 
died versus 86% of patients in the chemotherapy group [25].
Cytoreductive surgery is a standard part of national and international guidelines 
[25, 27, 28], hence surgical management with maximal therapeutic effort is the aim 
of treatment, even for patients with a higher tumour load, as survival of the patients 
has been clearly demonstrated [25].
3.2 Patient selection
The mainstay of treatment is a holistic approach to the patient’s care. The patient 
needs to fully understand the benefits, risks and alternatives to surgery. Consent for 
this procedure needs to be carefully considered and fully informed.
3.3 Clinical assessment
The patient needs to be assessed with regards to their ability to walk and carry 
out ordinary activities independently, which includes climbing a flight of stairs. The 
advice of the anaesthetist is valuable, and cardiopulmonary exercise testing (CPET) 
may also be required to determine the anaerobic threshold of the patient prior to 
major surgery [24].
Demographic characteristics which have to be considered when selecting 
patients are age, previous abdominal surgery, ASA score, presence of ascites, preop-
erative Ca125, preoperative level of haemoglobin, albumin, FIGO stage, histological 
cancer type [29].
The triage process of patients for debulking includes:
a. a suitable WHO Performance Status (PS) at the preoperative assessment.
b. absence of lung or multiple parenchymal liver metastases on the CT scan.
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c. exploratory laparoscopy did not demonstrate small bowel serosal disease or 
porta hepatis encasement [30].
Liu et al. [31, 32] reported that more than a quarter of women with advanced 
ovarian cancer treated with neoadjuvant chemotherapy (NACT) do not ever 
undergo cytoreductive surgery. Significant risk factors contributing to the inability 
to undergo surgery were advanced age, low albumin levels, frailty scores and exten-
sive disease of predominantly high-grade serous histology. The main reasons identi-
fied were extent of disease not amenable to surgery or lack of response to NACT, 
patient co-morbidities preventing surgery and extent of disease. The patients who 
did not have debulking surgery, had an over 3-fold increase in mortality of any 
cause, compared to those who had surgery at some point [31, 32].
In patients with advanced disease, there is a strong rationale to personalise the 
surgical treatment and implement predictive and prognostic scores [31]. The aim 
is to allocate the right treatment to the right patient, in order to avoid unnecessary 
iatrogenic damage [31].
Appreciation of potential impact on the quality of life (QoL) has to be thor-
oughly assessed and balanced against survival benefit.
3.4 Investigations
A pre-operative CT scan for the thorax, abdomen and pelvis with contrast is 
essential. The patients with disease progression with lung metastasis or three or more 
liver segments involvement should be triaged for neo-adjuvant chemotherapy strategy 
[24]. Tozzi et al. has shown that exploratory laparoscopy added to the CT scan could 
potentially identify porta hepatis peritoneal disease [33] as well as small bowel serosal 
involvement. Several advantages of the exploratory laparoscopy have been reported, 
amongst which a correct diagnosis based on the histology of the tissue biopsy, accurate 
evaluation of the spread of the disease, including the spread of small military disease, 
a better selection of the patients for ultra-radical surgery and a better planning of 
resources in view of the surgery [34]. The authors concluded that this combination of 
investigations is of a high reliability, and encouraged surgical outcomes [33, 34].
3.5 Diagnostic laparoscopy
Following confirmation of suitability for surgery based on the CT scan, it is rec-
ommended to consider an exploratory laparoscopy to rule out diffuse small bowel 
serosa deposits and porta hepatis encasement [24]. There are controversies around 
this approach, however it has been demonstrated [24] that the use of Palmer’s point 
and Hasson’s technique to enter the abdomen is an easy and safe technique. This is a 
short procedure, very informative, allowing a thorough assessment of the intraab-
dominal cavity, and helps in avoiding a laparotomy if the chances of no residual 
disease are unlikely.
3.6 Systematic abdominal exploration
A systematic approach is required, and this is performed by assessing in system-
atic manner.
a. In the upper abdomen the diaphragm, liver, with its Glisson’s capsule, falciform 
ligament, ligamentum teres, Morison’s pouch, the stomach, lesser omentum 
also known as gastro-hepatic ligament, spleen, tail of pancreas, porta hepatis 
also known as hepato-dudenal ligament, foramen of Winslow, and the coeliac 
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trunk needs to be assessed. The latter two can be examined by palpation at 
laparotomy only, and this represents a limiting factor.
b. In the mid abdomen the omentum is fully assessed, the ileocaecal junction 
is identified and small bowel is run u to the point of DJ junction (duodeno-
jeoujenal junction), as well as the root of the small bowel mesentery and the 
small bowel serosa. If the small bowel serosa is extensively affected requiring 
removal of a large part of the small bowel in order to achieve R0 (leaving a 
small bowel of less than 150 cm), a debulking procedure should be abandoned.
c. The lower abdomen (pelvis) - a thorough assessment looks at the extent of the 
disease in the pelvis starting with spread to the uterine body, fallopian tubes, 
round ligaments and sigmoid, with further assessment of the pouch of Douglas 
and the bladder peritoneum.
After all these assessments the conclusion can be withdrawn as whether the 
surgery will be beneficial and results in no residual disease. This often requires an 




A close collaboration and clear communication with the anaesthetist and 
the other members of the team are hugely important, as the preparation of 
the patient is paramount. The patient is positioned in Lloyd Davis with atten-
tion to avoiding common peroneal nerve injury/femoral nerve neuropraxia or 
lower limb compartment syndrome. The use of the correct retractor (i.e. Greys, 
Bookwalter) will also help in gaining an optimal access to the pelvis, but also to 
the right and left upper quadrants.
4.2 Intraoperatively
A midline laparotomy is always required in order to allow a good access to all 
the pelvic and intraabdominal areas mentioned above. An understanding about 
the radicality of the procedure is further required, and this is highlighted in 
Table 2 [35].
The majority of ovarian cancers present in advanced stages and are treated by 
debulking surgery and platinum-based chemotherapy. The disease starts in the 
pelvis, involving the ovaries, tubes, the uterus, and the bowel and then spreads to 
the upper abdomen. Once established that an R0 is feasible the procedure starts in 
the pelvis.
In the case all pelvic organs are matted, a technique is needed to remove the 
tumour with cancer free margins. To achieve the least residual disease, multivisceral 
pelvic and upper abdominal surgery is often necessary [36–39].
Ten steps of the en-bloc resection of the pelvis (Figure 2) are described below [24]:
1. Access to the retroperitoneal space: isolation of the ureter, ligation of the 
infundibulo-pelvic ligament.
2. Resection of sigmoid.
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3. Mobilisation of the sigmoid from the sacrum by coagulation and resection of 
the meso-sigmoid
4. Access to the pre-sacral space.
5. Mobilisation of the bladder peritoneum with access to the vesico-vaginal space.
6. Colpotomy of the anterior vaginal wall.
7. Retrograde resection of the parametria.
Classification Groups Criteria
NICE Standard Total abdominal hysterectomy, bilateral salpingo-oophorectomy, 
omentectomy (Figure 1), pelvic and/or para-aortic lymphadenectomy, 
bowel surgery outside the definition of ‘ultra-radical’ (localised colonic 
resection, non-multiple bowel resection)
Ultraradical Diaphragmatic stripping, extensive peritoneal stripping, multiple 
resections of the bowel (excluding localised colonic resection), liver 
resection, partial gastrectomy, cholecystectomy, splenectomy
Pomel Standard Hysterectomy, bilateral salpingo-oophorectomy, pelvic peritonectomy, 
total omentectomy, appendicectomy, pelvic and/or para-aortic 
lymphadenectomy
Radical Recto-sigmoid resection
Supra-radical Diaphragmatic stripping, liver resection, cholecystectomy, 
splenectomy, any digestive resection excluding recto-sigmoid resection
Table 2. 
Description of surgical radicality.
Figure 1. 
Total omentectomy.
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8. Colpotomy of the posterior vaginal wall, access to the recto-vaginal septum.
9. Dissection, coagulation and division of the meso-rectum.
10. Resection of rectum ± anastomosis.
A particular attention needs to be given to bowel resection. Recto-sigmoid resec-
tion (RSR) is the most commonly non-gynaecologic procedure performed. It can 
be associated with early postoperative complications, most severe being the break-
down of the anastomosis or anastomotic leak [36, 40, 41].
The literature reports 0.8% - 6.8% risk of anastomotic leak in patients who 
underwent bowel resection during debulking surgery for ovarian cancer [36]. 
Therefore, sigmoid rectum resection is sometimes accompanied by a diverting loop 
ileostomy (DLI) with the aim to reduce the anastomotic leak. This is not without 
complications, and although it is typically intended to be reversible, the non-rever-
sal rate of ileostomy is 9.5–35% in the colorectal literature [36, 42–46].
RSR is the resection of any large bowel segment from the pelvic brim to the anal 
canal. The decision to undertake RSR is made at the time of surgery and was usually 
part of an en-bloc resection of the pelvis [36, 47].
DLI is a loop of small bowel, 10–15 cm proximal to the ileocaecal junction, used 
to divert the faecal stream and protect the colorectal anastomosis. The indications 
for DLI are [29, 33]:
• multiple bowel resections.
• RSR < 6 cm from anal verge.
• non-tension free anastomosis.
• poor tissue quality.
• air spillage through the anastomosis at trans-anal air test.
DLI reversal was planned at the end of the chemotherapy and if the patient has 
three months disease-free interval verified on CT scan. The morbidity of DLI is 
Figure 2. 
En-bloc modified posterior pelvic exenteration-including bladder, pelvic, peri-ureteric peritoneum, uterus, 
cervix, tubes, ovaries and rectosigmoid.
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very challenging, and more for patients who are metabolically deranged, older age, 
low albumin level, fluid imbalance. DLI morbidity can delay chemotherapy due to 
dehydration. The optimal timing for reversal remains unclear, usually 6–8 weeks 
postoperatively [36]. End-colostomy is easier to manage than an end-ileostomy 
[36, 48], hence for the patients presenting with risk factors for non-reversal, a 
careful consideration should be given to the type of bowel diversion performed 
during debulking surgery [36, 47].
According to a study performed by Tozzi et al. [47] patients in IDS had a slightly 
higher rate of bowel diversion compared to patients in PDS group (46% vs. 26.5%). 
Also, patients in IDS were more likely to receive bowel diversion due to impaired 
tissue quality (44.8% vs. none) while patients in PDS were more likely to receive a 
bowel diversion when receiving multiple bowel resections (92.3% vs. 34.5%) [47].
Bowel resection has to be limited to what is required, as multiple bowel resec-
tions will increase the morbidity [29], as already mentioned above. The tumour 
must be excised whilst the blood supply is avoided. In order to safely do this, a 
technique is to dim the theatre light, assess the blood supply and identify the right 
colic, middle colic, left colic. Once the bowel resection is performed, further assess-
ment for potential ischaemic changes is required.
It is possible to perform small bowel mesenteric peritonectomy or excision of the 
mesocolon without the need to perform full bowel resection.
After the disease in the pelvis has been tackled the procedure continues in the 
upper abdomen. To achieve complete resection, extensive upper abdominal pro-
cedures are warranted. Strong evidence suggests that upper abdominal procedures 
improve the survival rates regardless of the time of the debulking [33, 49–55].
The upper abdomen is divided in right and left quadrant and a systematic 
approach is required. The assessment starts with the mobilisation of the liver 
(Figures 3–5), dividing the falciform ligament, the coronary ligaments in order to 
assess the posterior aspect of the liver.
Diaphragmatic peritonectomy (Figures 6 and 7) with or without pleurectomy, 
partial liver resection, cholecystectomy, splenectomy with or without distal pancre-
atectomy and resection of the tumour at the porta hepatis (PH) may be required in 
order to achieve complete resection [33].
Diaphragmatic assessment for cancer invasion is paramount. One of the key 
dilemmas is to decide which patient would benefit from full diaphragmatic resec-
tion, as opposed to peritonectomy only [56, 57]. Tozzi et al. performed a study on 
Figure 3. 
Mobilisation of the liver. Large xiphopubic incision required.
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170 patients who underwent diaphragmatic surgery and described a meticulous 
classification to reduce the morbidity but also achieve maximum cytoreductive 
effort in the upper abdomen. Soleymani majd et al. reported that in patients with 
diaphragmatic metastasis, 28% had disease spread to the muscle, and 20% of 
patients had full thickness disease involving the pleura [57–59]. Hence diaphrag-
matic peritonectomy alone would have left disease in the muscle and the pleura, 
and complete cytoreduction would not have been possible. The decision about full 
Figure 4. 
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thickness diaphragmatic resection versus diaphragmatic peritonectomy requires 
prospective studies balancing morbidity against survival benefits [56].
The porta hepatis (PH) shall always be assessed prior to laparotomy, as encasement 
of the vessels is an absolute contraindication to proceed with radical debulking surgery. 
Inspection and palpation of the portal vein, hepatic artery, and bile duct are required, 
along with assessment of the hepato-coeliac lymph nodes. The pringle manoeuvre 
should be performed prior to liver mobilisation to maximise surgical safety.
Resection of ovarian disease at the PH was feasible in 90.3% of patients in the 




Peritoneum after diaphragmatic peritonectomy (removal in one piece).
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tumour resection at the PH, moreover the resection of PH disease was effective, 
significantly contributing to a 90% rate of achieving R0. Raspagliese et al. [33, 60], 
along with this study [33] highlight the importance of routinely exploring the PH 
area, if aiming for complete cytoreduction.
The excision of lymph nodes beyond abdomen and pelvis is controversial, how-
ever leaving an enlarged/bulky lymph node despite all other maximal cytoreductive 
efforts, may mean that no residual disease status was not achieved. Removal of the 
cardio-phrenic lymph nodes has to be assessed on individual circumstances and 
localization of the lymph nodes. In the circumstance, that an enlarged pericardiac 
lymph node is noted, and the gynaecological oncologist is not trained or confident 
in removing it, then cardiothoracic expertise would be required in order to achieve 
complete cytoreduction. The Lion study intraoperatively randomly assigned 647 
patients with newly diagnosed advanced ovarian cancer (Stage IIB to IV) who had 
undergone macroscopically complete resection and had normal lymph nodes (both 
before and during surgery) to either undergo or not undergo lymphadenectomy. In 
total, 323 had lymphadenectomy whilst 324 did not. The median overall survival 
was 69.2 months in the non-lymphadenectomy group and 65.5 months in the 
lymphadenectomy group. The median progression-free survival was 25.5 months 
in both groups. Postoperative complications were more prevalent in the lymphad-
enectomy group. Therefore, the Lion study concluded that systematic pelvic and 
para-aortic lymphadenectomy in patients with advanced ovarian cancer, was not 
associated with longer overall or progression-free survival but was associated with 
a higher incidence of postoperative complications, when compared with those who 
had no lymphadenectomy [61].
Figure 8 illustrates the opening of the right pelvic side wall.
Surgical debulking in ovarian cancer (especially for advanced disease) has tra-
ditionally been performed via an open abdominal route. Laparoscopy in advanced 
ovarian cancer has mostly been used to explore the feasibility of a complete surgi-
cal resection [30]. However, there are a few recent studies in the literature, which 
report complete response to chemotherapy and no gross residual disease after a 
laparoscopic approach. In the past, concern about the use of laparoscopy included 
inadequate radicality, the risk of vaginal and/or port site metastasis secondary to 
Figure 8. 
Right pelvic side wall- exposure of lumbosacral and obturator fossae.
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tumour contamination and the use of CO2. In the recent reports, complete resection 
was achieved at laparoscopy, making it a potentially feasible alternative, warrant-
ing consideration [30]. Safe laparoscopy in advanced ovarian cancer consists of 
thorough preoperative preparation and study of the CT scan images, matching it 
with the laparoscopic findings, and exploring all peritoneal surfaces. Particular care 
needs to be taken in avoiding tumour contamination, seeking for cleavage planes in 
healthy tissue and minimising tumour manipulation. Endobags should be used to 
extract all specimens, which should be removed intact. Tumour extraction through 
the vagina is ill advised, if compliance is not adequate [30].
There are a number of well-known benefits of a laparoscopic approach, includ-
ing: reduced blood loss, decreased pain, earlier discontinuation of analgesia, shorter 
hospital stay, lower rate of complication and infection. Some researchers report that 
a short postoperative period is very important in the prognosis of cancer patients 
and affects survival [30, 62–66]. Surgery has been associated with an increased 
risk of metastasis and tumour recurrence. The main responsible mechanisms are 
tumour cell dissemination, shedding, enhanced adhesion, increased tumour growth 
secondary to reduced apoptosis, increased release of growth factors and angiogen-
esis, transient but profound suppression of cell-mediated immunity (CMI). The 
latter controls the minimal residual disease which is present at a cytological level 
in patients with ovarian cancer. The degree of surgical trauma is noted to correlate 
with immune depression and with tumour growth [30, 62–66]. Laparoscopy, how-
ever, causes reduced trauma and as a consequence a lower inflammatory response, 
an increased TH1 cytokine production, faster return to normal lymphocyte count 
and an absence of tumour growth factors in the serum [30, 65]. These effects 
contribute to a reduced recurrence rate [30, 66], as well as a faster recovery of the 
immune system in patients with ovarian cancer during their chemotherapy, as they 
are more prone to anaemia and infections [30, 66].
The data reported so far is for the use of laparoscopy in interval debulking 
surgery, there is no data on its use in primary debulking surgery [30].
5. Quality of Life
The Quality of Life (QoL) needs to be assessed after such a major and long 
surgery, which sometimes lasts up to ten hours. QoL questionnaires were sent out 
to the patients in the Lion study [61]. At the time of discharge, most patients had a 
poor quality of life, but this improved at follow up (at the end of chemotherapy).
An ultra-radical surgery with the aim of leaving no residual disease (R0) is not 
successful if the approach to the patient is not holistic; an assessment of whether the 
patient’s quality of life could be improved has to be performed. This surgery should 
be offered to suitable patients only. Du Bois et al. demonstrated in their study that 
the benefit was exclusively seen in patients with complete resection (R0) indicating 
the importance of both the optimal selection of the patients, and of centres with 
expertise and a high chance of achieving R0 [26, 67, 68].
In ovarian cancer surgery, a multidisciplinary approach is required for successful 
cytoreductive surgery, keeping the patient at the centre of care.
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